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Health disparitiesDespite its potential to improvemetabolic health outcomes, longitudinal physical activity (PA) patterns and their
association with cardiometabolic disease among people living with HIV (PLWH) have not been well character-
ized.We investigated this relationship among PLWH in the Centers for AIDSResearchNetwork of Integrated Clin-
ical Systems with at least one PA self-report between 2008 and 2015. The 4-item Lipid Research Clinics PA
instrument was used to categorize habitual PA levels as: Very Low, Low, Moderate, or High. We analyzed demo-
graphic differences in PA patterns. Multivariable generalized estimating equation regression models were fit to
assess longitudinal associations of PA with blood pressure, lipid, and glucose levels. Logistic regression modeling
was used to assess the odds of being diagnosed with obesity, cardiovascular disease (CVD), cerebrovascular dis-
ease, hypertension, diabetes, or multimorbidity. A total of 40,462 unique PA assessments were provided by
11,719 participants. Only 13% of PLWH reported High PA, while 68% reported Very Low/Low PA at baseline
and did not increase PA levels during the study period. Compared to those reporting High PA, participants
with Very Low PA had almost 2-fold increased risk for CVD. Very Low PA was also associated with several risk
factors associatedwith CVD,most notably elevated triglycerides (odds ratio 25.4), obesity (odds ratio 1.9), hyper-
tension (odds ratio 1.4), and diabetes (odds ratio 2.3; all p b 0.01). Low levels of PA over time among PLWH are
associated with increased cardiometabolic disease risk.nce; BF, black female; BM, black male; BMI, body mass index; CVD, cardiovascular disease; CFAR, Centers for AIDS Research;
diastolic blood pressure; EMR, electronic medical record; HDL-c, high-density lipoprotein cholesterol; HIV, human immunode-
ous; LDL-c, low-density lipoprotein cholesterol;MSM,menwhohave sexwithmen;OF, other female; OM, othermale; PA, phys-
leic acid; SBP, systolic blood pressure; WF, white female; WM, white male.
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documented among people living with HIV (PLWH).1–3 We reported
that while most PLWH gainweight during the first sixmonths of antire-
troviral therapy use, many continue to gain weight for up to two years
after beginning treatment.4 In the current United States epidemic,
over 2/3 of PLWH are diagnosed as overweight/obese (25% obese),
40% with hypertension, and 6% cardiovascular disease (CVD).4–6 CVD
and other cardiometabolic diseases are associated with increased mor-
tality risk in adults living with and without HIV infection7,8; thus these
alarming results highlight a need for effective interventions to prevent
and treat cardiometabolic disease among PLWH.
One potential intervention is to increase habitual physical activity
(PA), which is associated with decreased mortality and improved health
outcomes among the general population.9,10 Unfortunately, PLWH have
lower physical fitness levels compared to other vulnerable populations,11
and longitudinal studies conducted in PLWH have primarily focused on
specific exercise interventions rather than habitual physical activity.12,13
Thus it is unknown if the amount of PA needed for meaningful improve-
ment in cardiometabolic disease biomarkers andoutcomes is different for
PLWH versus those without HIV. Additionally, long-term data regarding
PA habits of PLWH are lacking, while cross-sectional studies of PA levels
that include smaller sample sizes from single sites reveal awide disparity
in self-reported activity levels.14–16 To develop effective PA strategies, we
require a greater understanding of the longitudinal PA patterns reported
by PLWH, and the minimal amount of activity needed to reduce cardio-
metabolic disease risk. Therefore, the objectives of this study were to
(1) describe PA patterns among PLWH, and (2) determine which cardio-
metabolic disease biomarkers/diagnoses are most influenced by PA pat-
terns in this population. To accomplish these objectives, we analyzed
PA and cardiometabolic disease data collected over 7.5 years from
11,719 PLWH in themultisite Centers for AIDS Research (CFAR) Network
of Integrated Clinical Systems (CNICS) cohort of PLWH in the United
States.Methods
This retrospective analysis was conducted in the United States from
CNICS.17 CNICS is a nationally distributed clinical cohort that includes
over 32,000 PLWH receiving routine clinical care. At regular intervals,
CNICS sites provide comprehensive data on demographics, laboratory
values, pharmaceutical history, HIV/AIDS clinical events, and comorbid
conditions collected from electronic medical records and other data
sources, including the CNICS clinical assessment of standardized
Patient-Reported Outcomes measured at 4–6 month intervals18,19 atseven CNICS sites. A rigorous, systematic quality assurance process is
in place to maintain this centralized database.
Participants
This study includes all CNICS participants who completed a clinical
assessment between January 2008 (first PA measures available) and
mid-July 2015. Inclusion criteria were: (1) at least one PA instrument
completed, (2) ≥19 years of age, and (3) height/weight were available.
Written, informed consent for CNICSwas obtained from all study partic-
ipants and documented at each site, and the protocol was approved by
the Institutional Review Board (IRB) at each site. Ethical approval for
this study was provided by the IRB at the University of Alabama at Bir-
mingham. Procedures were followed in accordance with the ethical
standards of the responsible committee on human experimentation (in-




Participants completed the 4-question, validated Lipid Research
Clinics (LRC) instrument to provide an estimate of self-reported PA.20
The LRC asks about respondents' perception, compared to peers, of PA
amount/intensity at work and outside of work. A 4-point scoring system
is used to classify activity levels as (1) high PA (vigorous activity ≥ 3 times
weekly), (2)moderate PA (active, but vigorous activity b 3 timesweekly),
(3) low PA (no vigorous activity but light activity perceived as equivalent
to peers), or (4) very low PA (sedentary). The 4-point scoring previously
identified physiologically relevant group differences in VO2max: High PA
41.9 ml/kg−1/min−1, Moderate 39.1 ml/kg−1/min−1, Low 33.2 ml/
kg−1/min−1, and Very Low 32.9 ml/kg−1/min−1.20
Clinical and laboratory parameters
Vital signs and laboratory values closest to the date (± 90 days) of
each PA assessment were included. Systolic (SBP) and diastolic (DBP)
blood pressure were measured at the beginning of patient care encoun-
ters as part of routine clinical care. As participant lab draws occurred
throughout the day, both fasting and non-fasting glucose and lipid
values (total cholesterol, LDL-c, HDL-c, triglycerides) were included.
Cardiometabolic diseases
We focused on five cardiometabolic outcomes with a prevalence of
at least 2% in the CNICS cohort: obesity, CVD, cerebrovascular disease,
hypertension, and diabetes – aswell asmultimorbidity. [1] Obesity. Par-
ticipants were considered obese with a body mass index (weight [kg]/
height [m2]) ≥ 30. [2] CVD. Participants were classified as having CVD
if they were diagnosed with a myocardial infarction centrally adjudi-
catedwithin CNICS.21 Briefly, two physicianswho are experiencedmyo-
cardial infarction reviewers adjudicate each event based on available
EMR data. If there is a discrepancy in the outcome, a third reviewer
will also adjudicate the event. Adjudication protocols were not yet de-
veloped for other CVD conditions, thus recorded diagnoses (yes/no) in
the EMR of chronic ischemic heart disease and congestive heart failure
were considered for CVD. [3] Cerebrovascular disease. Similar to other
large HIV cohorts, adjudicated stroke data were not available in CNICS.
Thus, a participant was considered to have cerebrovascular diseases
with a diagnosis in the EMR. [4] Hypertension. Hypertension was
based on the CNICS standard definition of a diagnosis of hypertension
and the presence of any antihypertensive medication, or the average
of at least 2 systolic blood pressure measurements ≥140 mmHg or dia-
stolic blood pressure measurements ≥90mmHg over 12months. Aswe
were unable to confirm whether all patients with hypertension or CVD
were taking medications as prescribed, we included participants with
both pharmaceutically treated and untreated conditions. [5] Diabetes.
We defined diabetes based on the following criteria: a) hemoglobin
A1c ≥6.5 OR b) use of a diabetes-specific medication such as insulin
OR c) use of a diabetes-related medication frequently but not exclu-
sively used to treat diabetes (e.g. biguanides) in the setting of also hav-
ing a diabetes diagnosis.22Multimorbidity.Multimorbiditywas computed as the presence of two or
more of the above 5 cardiometabolic diseases as well as chronic kidney
disease and cancer (HIV and non-HIV related). Chronic kidney disease
was added tomultimorbidity criteria despite b2%population prevalence
due to its association with physical activity and risk factors of poorly
controlled HTN and obesity.23 Presence of chronic kidney disease was
defined as an estimated glomerular filtration rate b60 ml/min/1.73 m2
for N3 months (2 values N90 days apart without an intervening normal
value), or a charted diagnosis of Stage 2, 3, 4, or 5 kidney disease. The
low number of total cancer cases in the CNICS cohort prohibited us
from analyzing the association of physical activity with cancer risk.
However, cancer diagnoses (classified as dichotomous yes/no) were
added to themultimorbidity criteria since physical activitymay be asso-
ciated with cancer risk and metabolic risk factors contributing to devel-
opment of other cardiometabolic conditions may also increase cancer
risk.24,25Biomarkers. We further investigated the association of physical activity
with available biomarkers of CVD risk, hypertension, and diabetes:
Total Cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, sys-
tolic blood pressure, diastolic blood pressure, and glucose levels.Independent variables
We examined patient demographic and HIV-related laboratory in-
formation including age, sex, self-reported race/ethnicity, CD4+ T-cell
count, viral load, HIV transmission risk factor (intravenous drug use,
men having sex with men [MSM]), antiretroviral therapy (ART) use
(yes/no), insurance status (public, private, uninsured), and mortality
(yes/no with confirmed date of death). The “d” drugs didanosine
(DDI), stavudine (D4T), and zalcitabine (DDC) may contribute to
mitochondrial toxicity and peripheral neuropathy that could impair
PA ability26,27; thus we included a dichotomous variable (yes/no)
representing whether a participant had ever been exposed to d-drugs.
Since pharmaceutical therapy may impact the laboratory values evalu-
ated,we documented each prescribedmedicine that could affect results,
with the list ofmedicines included for each laboratory value adjudicated
by two clinical providers (GB and JW).Statistical analyses
Descriptive characteristics were analyzed using chi-square tests,
one-way analysis of variance (ANOVA) or Kruskal-Wallis ANOVA.
Time of first PA assessmentwas considered the baseline for each partic-
ipant. We computed prevalence, expressed as unadjusted percentages,
for each cardiometabolic condition overall and by PA group. Because
race/sex interactions were observed for cardiometabolic disease out-
comes, a 6-level race/sex variable was created (black men, black
women,whitemen,whitewomen, othermen, otherwomen) for subse-
quent analyses. The “other” racial category was approximately 40% self-
reported Asian/Pacific Islander, 40% unidentified, 11% American Indian,
and 9% multiracial.
For each continuous laboratory outcome, generalized estimating
equationswere fit to estimate the longitudinal effect of PA on laboratory
variables over time after controlling for covariates described under “in-
dependent variables”. We also controlled for outcome-specific non-ART
medications – antihyperlipidemic agents, antihypertensives, oral hypo-
glycemic agents, insulin - prescribed. For cardiometabolic disease out-
comes, multivariable logistic regression was used to compute odds
ratio and 95% confidence intervals (CI) of the odds of developing each
cardiometabolic condition controlling for the above covariates. Obesity
was also a covariate in all models excluding those with multimorbidity
and obesity as the dependent variable. For all analyses, sitewas included
as a stratification factor and “High PA” was considered the referent
group. With a multilevel modeling approach, adjustment for multiple
comparisons was not performed.28 Due to the association of the ART
medication zidovudine (azidothymindine)withmyopathywe also con-
ducted a sensitivity analysis including “ever used AZT” as a covariate;
however, this variable was not associatedwith PA levels and had no im-
pact on the association between PA and cardiometabolic outcomes. In
all models, we further controlled for the following factors described
under “independent variables”: age, self-reported ethnicity, CD4+ T-
cell count, viral load, HIV transmission risk factor, ART use, insurance
status, and mortality. All data were analyzed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA) with a significance level of p b 0.05.Results
Demographics and PA patterns
Over 7 ½ years, a total of 40,462 unique PA assessments were pro-
vided by 11,719 CNICS participants, with 8157 providing ≥2 reports,
and 3029 completing ≥5 reports. There were no significant differences
in demographic characteristics by those who had completed different
numbers of PA assessments; thus descriptive statistics for all 11,719
participants at their initial assessment are presented in Table 1. At
time of first PA report, 26% reported being Very Low active, 42% Low ac-
tive, 19% Moderate active, and 13% High active. Very Low and Low PA
participants were younger, less likely to be male, more likely to report
black race, and weighed more compared to other PA categories
(p b 0.01). Approximately 54% of participants consistently reported
Very Low/Low PA and 19% consistently reported High PA at each
reporting period; thus themajority (73%) of respondents did not change
PA levels during the observation period. There was no increase in Mod-
erate/High PA over time. There was no difference in PA category fre-
quency by year of first PA report, and no difference by PA category in
the percentage of participants prescribed ART (87–88%, p = 0.50). Of
note, individuals identifying as transgender were more likely to report
Very Low PA (p = 0.04).
A slightly higher percentage of Very LowPA participants (23.7%) had
been exposed to d-drugs compared to other groups (range 20.5–21.4%).
Baseline CD4+ T-cell counts were significantly increased across PA cat-
egories (p b 0.01). Greater mortality was also observed in the Very Low
PA group compared to all other groups.
Table 1
Demographic characteristics and laboratory values (mean± SD or n (%)) at first physical activity assessment (stratified by physical activity level) for people livingwith HIV receiving care













Age (yrs) 43.8 ± 10.7 44.9 ± 10.2 43.7 ± 10.9 42.8 ± 10.5 43.1 ± 10.8 b0.01
Birth sex
Male 9772 (83.4) 2409 (24.7) 4067 (41.6) 1956 (20.0) 1340 (13.7) b0.01
Female 1947 (16.6) 649 (33.3) 890 (45.7) 221 (11.4) 187 (9.6)
Transgenderb 0.04
Yes 96 (1.3) 37 (38.5) 32 (33.3) 18 (18.8) 9 (9.4)
No 7104 (98.7) 1842 (25.9) 2863 (40.3) 1445 (20.4) 954 (13.4)
Race b0.01
% Black 3917 (33.4) 991 (25.3) 1873 (47.8) 586 (15.0) 467 (11.9)
% White 6735 (57.5) 1855 (27.5) 2643 (39.2) 1338 (19.9) 899 (13.4)
% Other 1067 (9.1) 212 (19.9) 441 (41.3) 253 (23.7) 161 (15.1)
% Hispanic ethnicity 1597 (13.7) 358 (11.8) 666 (13.5) 350 (16.2) 223 (14.8) b0.01
Body mass index 26.5 ± 5.5 27.0 ± 6.3 26.5 ± 5.5 26.3 ± 4.8 26.0 ± 4.7 b0.01
Health insurance b0.01
Uninsured 1167 (9.9) 279 (23.9) 477 (40.9) 240 (20.6) 171 (14.6)
Public 6171 (52.7) 1932 (31.3) 2552 (41.3) 1054 (17.1) 633 (10.3)
Private 3083 (26.3) 455 (14.8) 1416 (45.9) 643 (20.9) 569 (18.4)
Unknown 1298 (11.1) 392 (30.2) 512 (39.5) 240 (18.5) 154 (11.8)
Transmission risk factor b0.01
IVDU 1771 (15.1) 579 (32.7) 697 (39.4) 324 (18.3) 171 (9.6)
MSM 6976 (59.5) 1632 (23.4) 2956 (42.4) 1393 (19.9) 995 (14.3)
Heterosexual 2615 (22.3) 725 (27.7) 1170 (44.7) 402 (15.4) 318 (12.2)
Other/unknown 357 (3.1) 122 (34.2) 134 (37.5) 58 (16.3) 43 (12.0)
Study sitec b0.01
UCSD 3345 (28.6) 908 (27.1) 1351 (40.4) 677 (20.3) 409 (12.2)
UAB 2827 (24.1) 728 (25.8) 1358 (48.0) 402 (14.2) 339 (12.0)
UW 1697 (14.5) 455 (26.8) 704 (41.5) 312 (18.4) 226 (13.3)
UCSF 1093 (9.3) 353 (32.3) 432 (39.5) 197 (18.0) 111 (10.2)
Fenway Health 1028 (8.8) 194 (18.9) 359 (34.9) 285 (27.7) 190 (18.5)
UNC 918 (7.8) 216 (23.5) 383 (41.7) 193 (21.0) 126 (13.8)
John Hopkins 811 (6.9) 204 (25.2) 370 (45.6) 111 (13.7) 126 (15.5)
Clinical and laboratory parameters
SBP (mm Hg) 125.9 ± 15.4 125.2 ± 15.9 126.0 ± 15.6 126.4 ± 14.9 126.3 ± 14.1 b0.01
DBP (mm Hg) 78.7 ± 10.3 78.9 ± 10.5 78.9 ± 10.3 78.6 ± 10.2 78.2 ± 9.7 0.16
Total Cholesterol (mg/dL) 177.2 ± 42.7 176.4 ± 44.3 177.8 ± 43.3 177.5 ± 41.4 176.1 ± 39.2 0.60
LDL-c (mg/dL) 101.9 ± 33.7 100.6 ± 34.6 102.6 ± 33.4 102.4 ± 33.8 101.7 ± 32.6 0.20
HDL-c (mg/dL) 43.8 ± 16.4 41.7 ± 15.9 44.3 ± 16.2 44.3 ± 16.2 46.1 ± 17.7 b0.01
Triglycerides (mg/dL) 176.5 ± 180.5 196.2 ± 174.0 176.3 ± 211.6 164.7 ± 131.2 154.0 ± 130.8 b0.01
Glucose (mg/ml) 95.1 ± 30.9 97.8 ± 37.2 94.7 ± 30.2 94.2 ± 27.5 92.2 ± 22.9 b0.01
CD4+ T-cell count (cells/μl) 506.7 ± 294.3 488.6 ± 315.7 508.7 ± 293.3 517.0 ± 275.0 521.9 ± 278.2 b0.01
Plasma HIV RNA b 200 copies/ml 7675 (70.5) 1928 (68.5) 3242 (70.1) 1472 (72.6) 1033 (72.5) b0.01
d-Drug exposure (ever) 0.01
Yes 2533 (21.6) 724 (28.6) 1031 (40.7) 465 (18.4) 313 (12.3)
No 9186 (78.4) 2334 (25.4) 3926 (42.7) 1712 (18.7) 1214 (13.2)
Death during observation period b0.01
Yes 510 (4.4) 216 (42.4) 204 (40.0) 55 (10.8) 35 (6.8)
No 11,209 (95.6) 2842 (25.4) 4753 (42.4) 2122 (18.9) 1492 (13.3)
Other=American Indian, Asian, Asian/Pacific Islander, Pacific Islander, multiracial,missing; IVDU= intravenous drug use;MSM=menhaving sexwithmen; d-drug=didanosine, stav-
udine, zalcitabine.
SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL-c = low-density lipoprotein cholesterol; HDL-c = high-density lipoprotein cholesterol.
a One-way ANOVA for continuous measures and chi-square for categorical measures.
b n (%) only for sites (UCSD, UAB, Fenway Health) collecting data on transgender identify up to 2015 (n = 7200).
c Study sites: UCSD=University of California, San Diego; UAB=University of Alabama at Birmingham; UW=University ofWashington, Seattle; UCSF=University of San Francisco;
UNC = University of North Carolina at Chapel Hill.Clinical and laboratory parameters
Laboratory values at time of first PA report are shown in Table 1. No
significant differences were identified by PA group for DBP, total choles-
terol, or LDL-c. Very Low PA participants had slightly lower SBP
(125.2 mm Hg) compared to other groups (range 126.0–126.4 mm Hg).
Those in the Very Low PA group presented with significantly lower
HDL-c levels, higher triglycerides, and higher glucose compared to all
other groups (all at p b 0.01).
These differences persisted in longitudinal adjusted analyses (Fig. 1;
Table 2). When compared to the High PA category, a significantstepwise decrease in HDL-c was observed with Moderate (Estimate
−0.71; 95% CI −1.25, −0.17; p = 0.009), Low (Estimate −1.03; 95%
CI−1.54, −0.51; p b 0.001) and Very Low PA (Estimate−1.56; 95% CI
−2.17,−0.96; p b 0.001). An increase in triglyceride levels was also ob-
served for each PA group: Moderate (Estimate 7.78; 95% CI 1.96, 13.59;
p = 0.009), Low (Estimate 16.12; 95% CI 9.90, 22.34; p b 0.001), and
Very Low (Estimate 25.43; 95% CI 15.64, 35.22; p b 0.001). When
glucose was analyzed, the Low PA (Estimate 1.35; 95% CI 0.26, 2.45;
p = 0.02) and Very Low PA (Estimate 1.98; 95% CI 0.47, 3.49; p =
0.01) groups had higher levels over time compared to the High PA
group. Full models results are shown in Supplementary Table 1.
Fig. 1. Associations between physical activity levels and laboratory values over time among people living with HIV. Values are generalized estimating equations parameter estimates and
95% confidence intervals. Eachmodel was adjusted for site, first physical activity assessment, race/sex, Hispanic ethnicity, age group, insurance status, HIV risk factor, d-drug use, viral load
group, CD4 group, and lab specific non-antiretroviral therapy medications prescribed.Cardiometabolic disease diagnosis
We observed significant differences in the prevalence of five cardio-
metabolic diseases and multimorbidity by PA group (Fig. 2). Over 1/3
(35%) of all participants were obese, but obesity prevalence was signif-
icantly different between groups: High PA (27%); Moderate (31%), Low
(35%,) and Very Low (41%). Similar differences were observed with hy-
pertension, CVD, and cerebrovascular diagnoses (Fig. 2). Finally, while
24% of the High PA group had cardiometabolic multimorbidity, greater
prevalence was observed in other PA groups: Moderate (27%, p =
0.003), Low (31%, p b 0.001) and Very Low (40%, p b 0.001).
In adjusted models using High PA as the reference group (Table 2;
Supplementary Table 2), only the Very Low PA group differed in preva-
lence of cerebrovascular disease (OR 1.76; 95% CI 1.13–2.74). Both Low
and Very Low PA were associated with greater risk for hypertension,Table 2
Demographic and clinical characteristics associated with cardiometabolic outcomes and longitu
justed analyses. For diagnosed outcomes, each column shows adjusted odds ratios for separatem










High Reference Reference Reference Referen
Moderate 0.21 (−0.22, 0.64) 0.41 (0.11, 0.71)‡ 0.30 (−1.48, 2.08) 0.10 (−
Low −0.20 (−0.62, 0.21) 0.40 (0.13, 0.68)‡ 1.31 (−0.41, 3.03) 0.41 (−
Very low −0.64 (−1.11, −0.16)‡ 0.32 (−0.01, 0.63) 1.34 (−0.81, 3.48) −0.49
Diagnosis Obesity
(n = 9930; 3506
events)




(n = 9525; 3
events)
PA levelb
High Reference Reference Reference
Moderate 1.34 (1.13–1.58)† 1.16 (0.98–1.38) 1.42 (0.87–2
Low 1.48 (1.28–1.71)† 1.28 (1.10–1.49)‡ 1.38 (0.89–2
Very low 1.92 (1.64–2.24)† 1.43 (1.21–1.68)† 1.76 (1.13–2
⁎ p b 0.05.
‡ p b 0.01.
† p b 0.001.
a SBP= systolic blood pressure; DBP=diastolic blood pressure; LDL-c= low-density lipopr
as two or more diagnoses of obesity, CVD, cerebrovascular disease, hypertension, diabetes, chr
b PA = physical activity.CVD, and diabetes, while a stepwise increase in risk of obesity and
multimorbidity was observed across all PA categories. Participants
with Very Low PA experienced 1.5–2 times greater risk of obesity, hy-
pertension, CVD, and multimorbidity. In particular, the Very Low PA
group had a 2.3 times greater risk of being diagnosed with diabetes.
Discussion
This investigation revealed that low PA levels are associatedwith in-
creased risk for CVD and other related chronic diseases (i.e., obesity, hy-
pertension, cerebrovascular disease, diabetes, and multimorbidity).
Despite nation-wide efforts to promote PA, the majority (68%) of
PLWH reported Very Low/Low PA at baseline (compared to 49.8% of
the general population), and did not increase PA during the study
period.29 Unfortunately, only 13% of PLWH reported High PA, versusdinal changes in cardiometabolic disease biomarkers among people living with HIV in ad-
ultivariable logistic regression. For laboratory biomarkers, each column shows parameter








ce Reference Reference Reference
1.40, 1.61) −0.71 (−1.25, −0.17)‡ 7.78 (1.96, 13.59)‡ 0.25 (−0.89, 1.38)
1.03, 1.84) −1.03 (−1.54, −0.51)† 16.12 (9.90, 22.34)† 1.35 (0.26, 2.45)⁎




(n = 9525; 560
events)
Diabetes
(n = 9525; 976
events)
Multimorbidity
(n = 9933; 3252
events)
Reference Reference Reference
.31) 1.09 (0.74–1.60) 1.19 (0.87–1.62) 1.32 (1.10–1.58)‡
.13) 1.48 (1.07–2.06)⁎ 1.49 (1.14–1.94)‡ 1.42 (1.21–1.66)†
.74)⁎ 1.92 (1.37–2.70)† 2.32 (1.76–3.05)† 2.12 (1.80–2.50)†
otein cholesterol; HDL-c=high-density lipoprotein cholesterol; Multimorbidity is defined
onic kidney disease, or cancer.
Fig. 2. Prevalence (%) of cardiometabolic disease and multimorbidity (two or more diagnoses of obesity, CVD, cerebrovascular disease, hypertension, diabetes, chronic kidney disease, or
cancer) by physical activity category for 11,719 people living with HIV between 1/2008 and 12/2015. * = p b 0.05; ** = p b 0.01; *** = p b 0.001.31.2% of the general population.29 Additionally, we found that partici-
pants in study sites in the Northeast (Fenway Health and Johns Hop-
kins) reported slightly higher levels of High PA. Overall, these results
highlight the need to develop effective PA promotion strategies for
PLWH.
We identified a consistent association of Very Low/LowPAwith both
cardiometabolic disease biomarkers and outcomes. The only differences
in cardiometabolic disease risk for Moderate versus High PA were for
obesity and multimorbidity, suggesting that even moderate PA may be
sufficient to reduce risk for hypertension, cerebrovascular disease,
CVD, and diabetes. In particular, reporting Very Low PA (versus High
PA) was associated with higher glucose levels and almost 2.5 times in-
creased diabetes risk.
A recent meta-analysis in HIV-negative adults observed reductions
in type 2 diabetes risk of 26% with Moderate PA and 53% with High
PA.30 Yarasheski et al. also reported that exercise augments the effects
of pharmaceutical treatment in PLWH with diabetes.31 However, due
toHIV-related chronic inflammation, pharmaceutical and lifestyle inter-
ventionsmay be less effective in PLWHversusHIV–negative groups.14,32
Monroe and colleagues14 reported that while low PA was associated
with greater insulin resistance (e.g., higher HOMA-IR) regardless of
HIV status, men with HIV still had higher HOMA-IR levels at equivalent
levels of PA. Collectively, these results highlight uncertainty in exactly
how much PA is required to achieve an equivalent benefit in diabetes
prevention/treatment for this population.
PA level was associatedwith both hypertension and cerebrovascular
disease. This association may have been attenuated by pharmaceutical
interventions for blood pressure control. However, the tendencywe ob-
served to see lower blood pressure levels in those reporting Very Low
PA could be confounded by a greater prevalence of uncontrolled viremia
in this group, which was associated with lower odds of hypertension in
our study (Supplementary Table 2) and others.33 The impact of PA fre-
quency or type on HTN risk among PLWH who have not achieved viro-
logic suppression remains to be fully investigated.Our analysis also associated increased risk of CVD events and athero-
genic lipid profile with Low/Very Low PA. An inverse association be-
tween PA levels and CVD risk factors/outcomes has been reported in
PLWH and HIV-negative populations.34,35 PA is also associated with
higher HDL-c and lower triglycerides in HIV-negative individuals, possi-
bly due to augmentation of lipoprotein lipase activity in skeletal muscle
and adipose tissue. However, consistent with our results, two meta-
analyses in HIV-negative individuals reported minimal declines in
LDL-c and total cholesterol levels of 2900 men and 1715 women.36,37
Future investigations are required to determine to what extent PA can
reduce the risk of CVD, and the amount and domains of PA required to
meaningfully impact PLWH who have a higher-than-average risk for
CVD.
Participants reporting Very Low PA tended to weigh more, have
greater mortality, more exposure to d-drugs, and lower CD4+ T-cell
counts than other groups. We previously reported that women with
HIV have elevated body fat levels regardless of body weight, thus in-
creasing PAmay beparticularly beneficial for PLWH.38 Regarding the as-
sociation with CD4+ T-cell count, small transient declines in CD4+
counts are observed with both periods of rest and strenuous activity
in PLWH and -negative groups, possibly due to increased autophagy
with hypoxia.39,40 However PA interventions are associated with
increased CD4+ count in PLWH in some, but not all, studies.41,42 This
study supports the potential of exercise to complement ART-related
immunologic reconstitution as an area that requires additional
exploration.
With regard to sex, race, and ethnicity, females had lower PA levels
compared to males, and black participants more frequently reported
Very Low/Low PA compared to other groups. Previous reports have
identified similar patterns of sex or racial health disparities in PA levels
in the general population and PLWH,16,43 confirming the need for pro-
grams to reduce sex and race disparities in PA. Interestingly, we also de-
tected differences in PA for PLWH who identify as transgender among
the 7200 participants reporting on transgender status. Within groups,
only 9% of transgender participants identified as High PA compared to
13% of other participants, and 38% of transgender participants reported
Very Low PA compared to 26% of others. Few investigations have ex-
plored unique aspects of health behaviors and risks among transgender
individuals, particularly those with HIV. Fredriksen-Goldsen et al.44 re-
ported lower PA levels in transgender adults over age 50 compared to
lesbian, gay, and bisexual older adults, while Bryant and colleagues
found that compared to other members of the LGBT community, trans-
gender women in particular were at risk for low PA and poor diet.45 The
milieu of hormonal and body composition changes, combined with
unique barriers to healthy dietary and PA habits, could exacerbate car-
diometabolic disease risk in this population. Unfortunately, our small
sample limits the general applicability of these findings for transgender
PLWH. Additional research is needed to identify barriers, facilitators,
and metabolic factors that contribute to disparities in PA for the trans-
gender community.
Our findings are subject to certain limitations. Self-reported PA is
less accurate than objectively measured PA and can underestimate
Very Low/Low PA while overestimating High PA.46 However, this
would possibly mean that Very Low/Low PA is present in more than
the 68% of PLWH identified here, and further serves to emphasize the
need for PA promotion in this population. Additionally, as our PA data
collection only began in 2008, and were unable to determine a reliable
date of diagnosis for all cardiometabolic diseases, we are unable to con-
sider the impact of PA habits across the life course and throughout HIV
infection, which is an area of significant interest in disease prevention.
Despite these limitations, the present study benefited from several
strengths, including a large, diverse sample size inclusive of several geo-
graphic regions across the United States, and repeated PA measures
assessed over 7 ½ years of observation. The study included both bio-
markers and outcomes of cardiometabolic disease and provides strong
evidence that PA can have ameaningful impact on cardiometabolic dis-
ease in PLWH. These findings inform clinical practice by highlighting
subgroups of PLWH that may benefit from additional PA promotion as
well as risk factors that are more likely to be impacted when PA levels
change. Additional scientific exploration that determines the appropri-
ate domains and dose-response of PA for specific cardiometabolic dis-
ease, as well as strategies to most effectively implement PA programs
among PLWH, holds great potential to improve outcomes and reduce
health disparities in cardiometabolic disease risk among individuals liv-
ing and aging with HIV.
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